pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·3h ago·1 min read
save

EpilepsyGTx appoints Teresa Nunes as chief medical officer

Aug 7, 2026·read at STAT ↗Positive

EpilepsyGTx announced the hiring of Teresa Nunes to serve as its new chief medical officer. Nunes moves to the company after holding the same position at Allucent.

The appointment is part of a broader trend of personnel shifts within the pharmaceutical sector, as companies seek experienced leaders to guide clinical and regulatory strategies.

No additional details about the role or future initiatives were provided in the announcement.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Up and down the ladder: The latest comings and goings”

read at STAT ↗
457 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ABBVIEGILEADLILLYPFIZERRISING
topics
MelanomaRare Disease

related stories

  • 3h agoEnsoma cuts jobs, narrows focus to lead assetBioSpace
  • 6h agoSTAT+: Pharmalittle: We’re reading about Replimune’s melanoma drug, a Medicare policy change, and moreSTAT
  • 1d agoSTAT+: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group assertsSTAT
  • 2d agoRumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcommsBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive